Csa Medical Inc

CSA Medical, Inc. is a medical device company developing and manufacturing interventional liquid nitrogen spray cryotherapy systems for pulmonary use. Its lead product, the RejuvenAir System, is a cryosurgical device that delivers precise, metered doses ("metered cryospray") of -196C liquid nitrogen to targeted areas of the airways during a minimally invasive, often outpatient, bronchoscopic procedure. The system combines software-driven dosimetry with specialty catheters to flash-freeze and destroy damaged airway cells while preserving the extracellular matrix, which the company states enables healing with limited scarring and fibrosis and allows repopulation with healthy cilia and goblet cells.

The therapy targets COPD with chronic bronchitis, addressing mucus overproduction and dysfunctional cilia rather than symptoms alone. Company materials cite an estimated 16 million people with COPD in the United States, of whom over 9 million have a chronic bronchitis diagnosis, roughly 700,000 U.S. hospitalizations per year for chronic bronchitis symptoms or exacerbations, and approximately 23 million people with COPD in Europe with about 1.5 million COPD hospitalizations annually.

The RejuvenAir System is approved in the European Union and remains an investigational device in the United States, where it is limited by federal law to investigational use. It has been designated a Breakthrough Medical Device. The company is led by CEO Wendelin Maners and is headquartered at 131 Hartwell Avenue, Lexington, Massachusetts.

Business model

CSA Medical develops and manufactures proprietary cryotherapy capital equipment and single-use specialty catheters for interventional pulmonology, with the RejuvenAir System commercially approved in the EU and pursuing U.S. FDA premarket approval before a planned U.S. commercial launch.

Traction

The company announced its 500th metered cryospray procedure in February 2024, performed at the Froedtert & Medical College of Wisconsin health network as part of the SPRAY-CB pivotal trial. SPRAY-CB is a double-blind, sham-controlled, prospective, randomized trial enrolling across the United States at sites including Temple University, UC Davis Medical Center, UT Southwestern, El Camino Hospital, Beth Israel Deaconess, Sarasota Memorial, Medical University of South Carolina, Duke, Cleveland Clinic, University of Wisconsin, LSU Shreveport, University of Cincinnati, St. David's Medical Center, University of Maryland, Dartmouth-Hitchcock, Prisma Health-Midlands and Ohio State University. European study results were described as showing statistically significant and clinically meaningful improvements in patient symptoms and quality of life.

Latest developments

In September 2024 CSA Medical completed an oversubscribed $53 million Series D preferred stock financing co-led by TVM Capital Life Science and Yonjin Ventures, with existing shareholders SV Health Investors, Ascension Ventures, First Analysis, Blue Heron and Intersouth Partners participating; Dr. Luc Marengere of TVM and Dr. Deng Mao of Yonjin Ventures joined the board. A company release referenced on the newswire notes the submission of a Premarket Approval application for the RejuvenAir System following positive results from the pivotal SPRAY-CB trial.